This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

CSF biomarker profile and diagnostic value in vascular dementia


Paraskevas, G. P., Kapaki, E., Papageorgiou, S. G., Kalfakis, N., Andreadou, E., Zalonis, I., Vassilopoulos, D.


European Journal Of Neurology: The Official Journal Of The European Federation Of Neurological Societies, Volume: 16, No.: 2, Pages.: 205-211

Year of Publication



Background and Purpose: The differential diagnosis between vascular dementia (VD) and Alzheimer’s disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 (A beta 42) alone and their combinations to investigate their diagnostic value in the discrimination between VD and AD or MD.; Methods: The above CSF biomarkers were determined in duplicate and blind to the clinical diagnosis by double sandwich, enzyme-linked immunosorbent assay (ELISA) commercial kits (Innogenetics, Gent, Belgium) in 92 AD patients, 23 VD patients, 17 patients with MD and 68 controls.; Results: Alzheimer’s disease and MD showed increased levels of tau(T), tau(P) and reduced levels of A beta 42 as compared with the controls. The best discrimination between VD and AD or MD was achieved by the combination of all three biomarkers, correctly classifying >or=85% of patients, either in the form of a discriminant function or in the form of the tau(T) x tau(P-181)/A beta 42 formula.; Conclusions: Cerebrospinal fluid biomarkers may be a useful adjunct for the discrimination between AD/ MD and VD in every day clinical practice.;

Bibtex Citation

@article{Paraskevas_2009, doi = {10.1111/j.1468-1331.2008.02387.x}, url = {}, year = 2009, month = {feb}, publisher = {Wiley-Blackwell}, volume = {16}, number = {2}, pages = {205--211}, author = {G. P. Paraskevas and E. Kapaki and S. G. Papageorgiou and N. Kalfakis and E. Andreadou and I. Zalonis and D. Vassilopoulos}, title = {{CSF} biomarker profile and diagnostic value in vascular dementia}, journal = {European Journal of Neurology} }


aged, alzheimer disease, biological markers, cerebrospinal fluid, dementia, dementia vascular, diagnosis, diagnosis, differential, diagnostic use, differential, female, humans, male, tau proteins

Countries of Study


Types of Dementia

Alzheimer’s Disease, Dementia (general / unspecified), Vascular Dementia

Types of Study

Case Control Study

Type of Outcomes


Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Biological Testing